Zhongsheng Pharmaceutical Co., Ltd.: RuiChuang liver disease innovative medicine, a subsidiary, obtained the US patent certificate

On January 17, Zhongsheng pharmaceutical released a notice that Zhongsheng RuiChuang, the holding subsidiary of the company, received a patent certificate issued by the US patent and Trademark Office, with the patent name of "pyrrolidine derivative as ppar activator" The patent is the compound patent of zsp0678 project, the second innovative drug distributed in the field of liver diseases by Zhongsheng RuiChuang, a subsidiary of Zhongsheng pharmaceutical holding company It belongs to the core patent of the project Zsp0678 is an innovative drug for the treatment of nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), which has a clear mechanism of action and independent intellectual property rights At present, zsp0678 tablet has been approved by the National Drug Administration (nmpa) for the clinical trial of treating Nash The phase I clinical trial of healthy volunteers in China has been started, and the first volunteer group and drug administration have been completed The work of clinical trial is actively advancing according to the plan; zsp0678 The application for clinical trial registration of "treatment of primary biliary cholangitis (PBC)" was accepted by nmpa, and the acceptance notice has been received The compound patent of zsp0678 project has been authorized by the United States, which is another patent authorization after the compound patent of the project has been authorized by Australia The global intellectual property protection system of zsp0678 project has been gradually improved Adorable adorable